Literature DB >> 19601689

The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD.

Julie A Dopheide1.   

Abstract

Pharmacotherapy plays a primary role in the management of attention-deficit/hyperactivity disorder (ADHD), despite the availability of effective behavioral interventions. Psychostimulants are the most commonly prescribed form of pharmacotherapy for patients with ADHD and their benefits in managed care are severalfold, leading not only to symptom resolution and improved quality of life for patients, but also reduced costs for payers and purchasers. The use of these agents requires careful consideration and management by health plan stakeholders for optimal effectiveness. Concerns regarding medication adherence, in addition to the potential for diversion and abuse of psychostimulants, highlight the importance of effective pharmacotherapy management in patients with ADHD. Initiatives promoting medication adherence, such as patient/parent education, provider follow-up, and adverse effect management, are crucial for ensuring treatment success. Once-daily, extended-release formulations of stimulants may also contribute to improving medication adherence, as may managed care pharmacy interventions such as pharmacy database monitoring.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19601689

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  5 in total

1.  Management of newer medications for attention-deficit/hyperactivity disorder in commercial health plans.

Authors:  Dominic Hodgkin; Constance M Horgan; Amity E Quinn; Elizabeth L Merrick; Maureen T Stewart; Laurel K Leslie
Journal:  Clin Ther       Date:  2014-11-14       Impact factor: 3.393

Review 2.  Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options.

Authors:  Paul Hodgkins; Monica Shaw; David Coghill; Lily Hechtman
Journal:  Eur Child Adolesc Psychiatry       Date:  2012-07-05       Impact factor: 4.785

3.  Prescription, dispensation and marketing patterns of methylphenidate.

Authors:  Edson Perini; Daniela Rezende Garcia Junqueira; Lorena Gomes Cunha Lana; Tatiana Chama Borges Luz
Journal:  Rev Saude Publica       Date:  2014-12       Impact factor: 2.106

Review 4.  Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges.

Authors:  Frank A López; Jacques R Leroux
Journal:  Atten Defic Hyperact Disord       Date:  2013-04-06

Review 5.  Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review.

Authors:  Tamás Treuer; Luis Méndez; William Montgomery; Shenghu Wu
Journal:  Neuropsychiatr Dis Treat       Date:  2016-05-03       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.